Clinical trials: High Blood Sugar
Metabolic Syndrome, Diabetes Mellitus, Type 2
Induced and Controlled Dietary Ketosis as a Regulator of Obesity and Metabolic Syndrome Pathologies
Original research article entitled Induced and Controlled Dietary Ketosis as a Regulator of Obesity and Metabolic Syndrome by Madeline Gibas for consideration for publication in a clinical journal.
- Conditions
- Metabolic Syndrome, Diabetes Mellitus, Type 2, Pre Diabetes
- Trial name
- NCT03047447
- Testing
- Dietary Ketosis: Regulator of Obesity and Metabolic Syndrome
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bristlecone Behavioral Health, Inc.
Type I Diabetes
Type 1 Diabetic Post Prandial Glycemia Evaluation Using an Algorithm
The aim of this study is to demonstrate the efficacy of an algorithm to anticipate the post prandial glycemic profile in type I diabetic patient.
- Trial name
- EGHYA (NCT05151770)
- Testing
- Measure of glycemia levels and comparison to algorithm predictions
- Where
- 2 sites in France
- Volunteers
- 40 people
- Sponsor
- M-DT1
Diabetes Mellitus, Non-Insulin-Dependent, Hyperglycemia
Bioequivalence Study Of Glucotrol XL 2.5 Mg Tablets
The objective of this study is to determine the bioequivalence of Glipizide GITS (Glucotrol XL) 2.5 mg tablets manufactured at the Brooklyn, New York facility versus tablets manufactured at the facility in Barceloneta, Puerto…
- Trial name
- NCT00550329
- Testing
- Glipizide GITS
- Where
- Singapore
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes, Hyperglycemia
Pivotal Study of the Intravenous Blood Glucose (IVBG) System, In-Clinic Setting
The purpose of this study is to evaluate safety and accuracy of the IVBG System (the "System") when used to track blood glucose in insulin treated subjects with diabetes mellitus in an in-clinic setting for up to 72 hours (per…
- Trial name
- NCT00925080
- Testing
- IVBG
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- DexCom, Inc.
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to metformin, over a period of 24 weeks of treatment, followed by an extension.
- Trial name
- GETGOAL-M (NCT00712673)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Metformin
- Where
- 16 sites in United States, Australia and 14 more
- Volunteers
- 680 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients
This was a four month dose ranging study followed by a 24 to 48 month extension at the selected dose to characterize the safety and efficacy of the injectable IL-1B (interleukin 1, beta) antagonist canakinumab in the treatment of…
- Trial name
- NCT00900146
- Testing
- Canakinumab, Metformin
- Where
- 106 sites in United States, Argentina and 12 more
- Volunteers
- 556 people
- Sponsor
- Novartis
Pre-diabetes
7-Ketolithocholic Acid in Prediabetes
7-Ketolithocholic Acid, a naturally occurring bile acid, is a novel food currently under investigation for potential metabolic benefits, including glucose-lowering effects.
- Trial name
- NCT07650123
- Testing
- 7-KLCA, Diet and Physical Activity
- Where
- 8 sites in Italy
- Volunteers
- 100 people
- Sponsor
- ICE S.p.A.
Diabetes Mellitus, Type 2
Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917
This study will compare glucose lowering with CS-917 compared to placebo after 3 months of treatment
- Trial name
- NCT00290940
- Testing
- CS-917, metformin hydrochloride, pioglitazone
- Where
- 66 sites in United States
- Volunteers
- 400 people
- Sponsor
- Daiichi Sankyo
High Blood Sugar, Metabolic Syndrome
Effect of ANKASCIN 568-P Products on Decreasing HbA1c and Regulating Blood Glucose
This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (24 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)
- Trial name
- NCT05737342
- Testing
- ANKASCIN 568-P Red yeast rice capsules
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- SunWay Biotech Co., LTD.
Trauma, Stress Induced Hyperglycemia
Stress Induced Hyperglycemia In Trauma
The clinical relevance of the observed stress induced hyperglycemia in trauma patients remains unclear. The earlier studies suggested the implications of cytokines in stress induced hyperglycemia and the outcomes after trauma.
- Conditions
- Trauma, Stress Induced Hyperglycemia, Diabetes Mellitus
- Trial name
- SIHG (NCT02999386)
- Where
- Qatar
- Volunteers
- 300 people
- Sponsor
- Hamad Medical Corporation
Type 1 Diabetes, Pancreatectomy; Hyperglycemia
Collection of Human Liver Biopsy and Whole Blood Samples From T1DM, TP or PP Patients for Potential Use for Insulin Producing Cells in Future Clinical Studies
In this study, liver samples will be collected, processed and stored in a specialized, clinical grade, cell bank for potential future clinical use.
- Trial name
- NCT04038931
- Testing
- Liver biopsy collection
- Volunteers
- 20 people
- Sponsor
- Orgenesis Ltd.
Diabetes Mellitus, Type 2
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients
The purpose of this study is to assess the safety and tolerability of MSDC-0602 and to evaluate the reduction in fasting plasma glucose in patients with Type 2 diabetes.
- Trial name
- NCT01280695
- Testing
- MSDC-0602 100 mg, MSDC-0602 250 mg, Pioglitazone
- Where
- 14 sites in United States
- Volunteers
- 129 people
- Sponsor
- Metabolic Solutions Development Company
Diabetes Mellitus, Non-Insulin-Dependent
The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)
The primary objectives of the ORIGIN study were: To determine whether insulin glargine-mediated normoglycemia can reduce cardiovascular morbidity and/or mortality in people at high risk for vascular disease with either Impaired…
- Trial name
- ORIGIN (NCT00069784)
- Testing
- insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), reusable pen device for insulin injection
- Where
- 40 sites in United States, Argentina and 38 more
- Volunteers
- 12,537 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus, Hypercholesterolemia
Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.
This is a 16-week double-blind, placebo-controlled (for colesevelam hydrochloride (HCl)) study in the type 2 diabetic subjects and pre-diabetic subjects.
- Conditions
- Type 2 Diabetes Mellitus, Hypercholesterolemia, Pre-diabetes
- Trial name
- NCT00570739
- Testing
- Metformin HCl tablets and Colesevelam tablets, Colesevelam
- Where
- 31 sites in United States, Colombia and 2 more
- Volunteers
- 502 people
- Sponsor
- Daiichi Sankyo
Diabetes Mellitus, Type 2, Pre-diabetes
Dietary Intervention in Type-2 Diabetes and Pre-Diabetes
The primary purpose of this research is to demonstrate the therapeutic effects of implementing a well-formulated low carbohydrate lifestyle program over 2 years in patients with type 2 diabetes, pre-diabetes, and metabolic…
- Conditions
- Diabetes Mellitus, Type 2, Pre-diabetes, Metabolic Syndrome
- Trial name
- NCT02519309
- Testing
- Virta Program
- Where
- United States
- Volunteers
- 465 people
- Sponsor
- Virta Health
Diabetes, Diabetes Mellitus, Type 1
Observational Study to Assess the Efficacy and Safety of NovoRapid™ Flexpen™
This study is conducted in Asia. The aim of this observational study is to collect efficacy and safety data in diabetic patients with acute hyperglycemia using NovoRapid™ FlexPen™ as per normal clinical practice.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00675220
- Testing
- insulin aspart
- Where
- Philippines
- Volunteers
- 373 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation
This study will evaluate the safety, tolerability and efficacy of AT-1501 in an immunomodulation regimen in adult patients with T1D undergoing an islet cell transplant.
- Trial name
- NCT04711226
- Testing
- AT-1501
- Where
- Canada
- Sponsor
- Anelixis Therapeutics, LLC
Type 1 Diabetes Mellitus, Sleep Quality
Safety and Effectiveness of the Luna System in People With Type 1 Diabetes Mellitus
The purpose of this research is to evaluate the effect of a wearable insulin pump on blood sugar levels during sleep. The study device works with continuous glucose monitors (CGM) to calculate and deliver rapid-acting insulin…
- Trial name
- AID4MDI (NCT06627517)
- Testing
- Episodic overnight patch pump
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Luna Diabetes
Diabetes Mellitus
Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus
The purpose of the study is to compare the effect of adding alogliptin, once daily (QD), to the ongoing treatment regimen of pioglitazone HCl and metformin in patients with inadequate glycemic control.
- Trial name
- NCT00432276
- Testing
- Alogliptin, Pioglitazone, Metformin
- Where
- 86 sites in United States
- Volunteers
- 803 people
- Sponsor
- Takeda
Type 1 Diabetes Mellitus (T1DM), High Level of Sugar (Glucose) in the Blood
A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone
This Phase 3 study was designed to demonstrate the net benefit of sotagliflozin versus placebo in patients with Type 1 Diabetes (T1D).
- Trial name
- inTandem3 (NCT02531035)
- Testing
- Sotagliflozin
- Where
- 135 sites in United States, Argentina and 17 more
- Volunteers
- 1,405 people
- Sponsor
- Lexicon Pharmaceuticals